...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Phase 1b/2 trial expected to initiate 1Q 2019

Yes it did but better at $0.83 than $25.00 as that's what I feel they will be worth by this fall. 

Just my opinion

Share
New Message
Please login to post a reply